Form 8-K - Current report:
SEC Accession No. 0001193125-24-258006
Filing Date
2024-11-14
Accepted
2024-11-14 07:35:32
Documents
15
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d855965d8k.htm   iXBRL 8-K 27703
2 EX-99.1 d855965dex991.htm EX-99.1 33320
  Complete submission text file 0001193125-24-258006.txt   230407

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA snse-20241114.xsd EX-101.SCH 3872
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE snse-20241114_def.xml EX-101.DEF 14097
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE snse-20241114_lab.xml EX-101.LAB 23426
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE snse-20241114_pre.xml EX-101.PRE 15130
18 EXTRACTED XBRL INSTANCE DOCUMENT d855965d8k_htm.xml XML 5603
Mailing Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850
Business Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 (240) 243-8000
Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39980 | Film No.: 241457218
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)